EQL Pharma AB

Rapporter

Visar 1 grupper

  1. Bokslutskommuniké Q4 2026

    ENSV
    →

    Financial Performance

    • Q4 net sales amounted to 120.2 MSEK, an increase of 6% from 113.3 MSEK in the previous year.
    • Full-year net sales reached 432.7 MSEK compared to 373.5 MSEK in the previous year.
    • Q4 EBIT was 5.1 MSEK (23.0 MSEK), with an operating margin of 4% (20%).
    • Full-year EBIT was 48.7 MSEK (67.4 MSEK).
    • Q4 EBITDA margin was 10% (25%).
    • Cash and cash…

    Öppna rapport